Navigation Links
Pharmos Corporation Reports 2009 Third Quarter Results
Date:11/12/2009

t the current cash and cash equivalents, totaling $1.3 million as of September 30, 2009, will be sufficient to support the Company's currently planned continuing operations at least through December 31, 2009. The Company is working on securing cash resources to extend operations beyond December 31, 2009. Cowen and Company have been retained as advisors to help accelerate the process of a partnership arrangement for our lead compound, Dextofisopam. Additionally any proceeds for the sale of the New Jersey NOL's are expected to extend operations beyond December 31, 2009. The Company's expected cash expenditures in the last quarter of 2009 will be less than the first three quarters of 2009 as the Dextofisopam Phase 2b trial completed patient treatment in July and statistical analysis was completed in September 2009. The majority of ongoing costs will be general and administrative which will be significantly less than funding a clinical trial. The Company routinely pursues various funding options, including additional equity offerings, equity-like financing, strategic corporate alliances, business combinations and the establishment of product related research and development limited partnerships, to obtain additional financing to continue the development of its products and bring them to commercial markets. On April 21, 2009, the Company completed a private placement of common stock and warrants. At the closing, the Company issued 18,000,000 shares of common stock and warrants exercisable for an additional 18,000,000 shares of common stock for an aggregate purchase price of $1,800,000. The exercise price of the warrants, which have a five-year term, is $0.12 per share. The details of the financing, made by existing investors and current board members, are described in Note 2 to the financial statements. This financing would also support additional efforts to negotiate a strategic partnership or license arrangement with a pharmaceutical company. This is consistent wit
'/>"/>
SOURCE Pharmos Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Pharmos Issues Business Update on Dextofisopam Trial and Financing
2. Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream
3. MedCath Corporation Reports Fourth Quarter Earnings
4. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
5. Dr. John Mills and Joseph Gentile Join Board of Directors of ChanTest Corporation
6. Volcano Corporation Presentation at Canaccord Adams Conference to Be Webcast
7. Raptor Pharmaceutical Corporation Announces Presentation of Data for NGX426, a Novel, Non-Opioid Oral Analgesic, at Neuropathic Pain Conference
8. China National Medicines Corporation Issues Milestone Purchase Order for 12,000 STA Systems
9. China Medicine Corporation to Acquire Pharmaceutical Manufacturer in Guangzhou
10. MedCath Corporation to Hold Conference Call on Fourth Quarter Results
11. DURECT Corporation Invites You to Join its Third Quarter 2009 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Mass. , Sept. 19, 2014  Alere Inc. ... rapid diagnostics, issued the following statement today in support ... Antibiotic-Resistant Bacteria. "As the global leader in ... for establishing a national strategy to address the serious ... to work with the Administration on initiatives to promote ...
(Date:9/19/2014)... MINNEAPOLIS and ORLANDO, Fla. ... data supporting Inspire therapy continues to grow, with the ... paper published on-line in Otolaryngology – Head ... therapy causes a worsening of both objective and subjective ... to directly attribute Inspire therapy for the reduction in ...
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced that David J. ... BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on Friday, ... The conference will take place at the Millennium Broadway ... A live and archived webcast of the ...
Breaking Medicine Technology:Alere Applauds President's Executive Order Combating Antibiotic-Resistant Bacteria 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3
... services for Cordex,s ATPace arrhythmia drug to be provided ... Pharma, Inc. (OTC Bulletin Board: CDXP) announced today that ... equity agreement with Cato BioVentures. As part of this ... arrange for Cato Research to perform regulatory services and ...
... be useful in treatment for degenerative disc disease LAS VEGAS, ... disease, sends millions of people to their doctor. In fact, ... do so because of disc degeneration. And part of the ... In their quest to discover ways to stop or reverse ...
Cached Medicine Technology:Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures 2Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures 3Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures 4Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures 5Cordex Pharma Announces Strategic Master Services Equity Agreement With Cato BioVentures 6Aching Back? Cholesterol Medication Might Help 2Aching Back? Cholesterol Medication Might Help 3
(Date:9/21/2014)... 2014 High in the rugged Gore ... and able-bodied athletes rafted the Colorado River, rode mountain ... in pursuit of outdoor adventure. At the September 12-14 ... T.E.A.M. Sports, disabilities proved to be no more than ... three stage event. , Each participating team of five ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 “Cluster headaches ... so intense and difficult to resolve,” said Steve Young ... can't think of a pain that is more intense.” ... suffers from cluster headaches, or migraines, that medical research ... the serotonin system,” he added. , Serotonin (5-HT, 5-hydroxytryptamine) ...
(Date:9/21/2014)... Mills, Md. (PRWEB) September 21, 2014 Faculty ... school with a coed preschool in Owings Mills, Md., kicked ... wellness with Garmin Vivofit bands. GFS is the first independent ... steps taken, calories burned and even sleep patterns— as part ... a Baltimore area running and walking specialty chain. The Vivofit ...
(Date:9/21/2014)... Top10BestSEOHosting.com, a leading review website, has recently announced ... most recommended hosting suppliers for the webmasters worldwide ... , “Don’t waste your time on searching ... hosting companies to you,” the IT manager of ... are the most recommended suppliers for everyone. A ...
(Date:9/20/2014)... NV (PRWEB) September 21, 2014 ... Dr. Kenneth Pullman that is helping thousands of people ... diabetes symptoms without shots, pills, or prescriptions has caught ... , “There are currently tens of millions of ... Type 1 and Type 2 diabetes, and unfortunately, big ...
Breaking Medicine News(10 mins):Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3Health News:Homeostasis: Equinox Serotonin (5HT) Headache Stories ~ New on the Bryan William Brickner Blog 2Health News:Garrison Forest School Leader in Independent School Wellness Programs 2Health News:Leading Review Website Top10BestSEOHosting.com Unveils The Best Hosting Suppliers In September 2Health News:Diabetes Protocol: Review Exposes Kenneth Pullman’s Breakthrough Discovery About Diabetes Management 2
... The Speaker of Lok Sabha, Shri Somnath Chatterji has said ... priority in policy making and implementation of programmes. // ... the country and the children at Vaatsalaya Mela here today, ... that still women and children went struggling for their rightful ...
... certain inhaled asthma medications and similar chemicals produced in ... worsen conditions like lupus, heart failures, asthma and other ... led by Raymond Penn, Ph.D., and Matthew Loza, Ph.D, ... out the research, found that beta-agonists, such as those ...
... engaging people cured of leprosy to fight the stigma of the ... of leprosy in the state has fallen to 1.56 percent in ... 'Lok Doots' (Messenger of People), as the cured are called, have ... ,For instance, the prevalence rate in Ranchi has gone up ...
... cardiac arrest is a common and deadly event. Twenty percent of ... a sudden cardiac arrest; //barely 5% of people who have one ... comes out of the blue, but a new study suggests that ... 2006 issue of the Harvard Heart Letter. ,Studying cardiac arrest ...
... The Massachusetts Biologic Laboratories (MBL) of the University of ... India today announce //the formation of an historic collaboration ... approach for preventing rabies in people. ,The institutions ... antibody (MAB) created by scientists at the MBL, in ...
... often multi-tasking and walking the tightrope to make a success ... they can chew! Though, such qualities //are the epitome of ... a pat on the back for such back-breaking endeavors. ... ill-health due to the build up of stress and over ...
Cached Medicine News:Health News:Women and Children Issues Should Get Priority in India 2Health News:The Immune System May Be Altered By Certain Chemicals 2Health News:International Collaboration Takes Aim at Rabies 2Health News:International Collaboration Takes Aim at Rabies 3
Post-Surgical compression garments...
Our Osteomark® ELISA kits provide a quantitative measurement of cross-linked N-telopeptides of type I collagen (NTx) as an indicator of bone resorption, with higher levels in serum or urine sampl...
... that quantitatively measure two important cardiac risk ... serum or plasma homocysteine level is increasingly ... factor for cardiovascular disease. And numerous studies ... levels of Lp(a) with increased risk of ...
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
Medicine Products: